Clinical trials: Colonic Disease
Solid Tumor
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
This is a first in human, single arm, open label, Phase 1a/1b study to determine the safety, feasibility, and efficacy of a single dose of NeoTCR-P1 T cells in participants with solid tumors.
- Trial name
- NCT03970382
- Testing
- NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- PACT Pharma, Inc.
Metastatic Colorectal Cancer
A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer
This is an open-label, parallel designed study to assess the pharmacokinetics, safety and tolerability of the single-dose and multi-dose of a recombinant anti-EGFR monoclonal antibody (CPGJ602) in patients with at least one prior…
- Trial name
- NCT03356158
- Testing
- CPGJ602, Cetuximab
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Ulcerative Colitis
New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis
The purpose of this study is to establish the efficacy and safety of a new tablet formulation and dosing regimen of balsalazide disodium dosed twice daily in achieving clinical improvement in subjects with mildly to moderately…
- Trial name
- NCT00269438
- Testing
- 5 ASA, enemas, suppositories, corticosteroids
- Where
- 66 sites in United States
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Diarrhea-predominant Irritable Bowel Syndrome
Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
This study is being conducted to evaluate in participants with diarrhea-predominant Irritable Bowel Syndrome (IBS-D) the abdominal pain response to BOS-589 after 4 weeks of treatment and to evaluate the overall safety and…
- Trial name
- NCT03977155
- Testing
- BOS-589
- Where
- 58 sites in United States
- Volunteers
- 133 people
- Sponsor
- Boston Pharmaceuticals
Pharmacokinetics, Safety Issues
A Clinical Study With Adalimumab Biosimilar
The study aims to evaluate the pharmacokinetic profile, safety profile, and immunogenic potential of adalimumab of a new citrate-free formulation of adalimumab (Adalimumab Richmond) [Test Product] vs.
- Trial name
- NCT06291948
- Testing
- Humira® (adalimumab) AC Pen [Reference Product], Adalimumab Richmond [Test Product]
- Where
- Argentina
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Laboratorios Richmond S.A.C.I.F.
Constipation, Signs and Symptoms, Digestive
Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients
To characterize the pharmacokinetics (PK) of naloxegol after single oral dose and through population PK in paediatric patients with opioid induced constipation (OIC) or at risk of OIC.
- Trial name
- NCT02099591
- Testing
- Naloxegol
- Where
- 16 sites in Denmark, Israel and 3 more
- Volunteers
- 61 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Colorectal Cancer (CRC), Gastric Cancer
A Study of SC-007 in Subjects With Advanced Cancer
This is a multicenter, open-label, Phase 1 study in participants with colorectal cancer (CRC) or gastric cancer to study the safety and tolerability of SC-007 and consists of Part A (dose regimen finding) in participants with CRC…
- Trial name
- NCT03253185
- Testing
- SC-007
- Where
- 7 sites in United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- AbbVie
Colorectal Cancer
GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin
The purpose of this study is to determine the efficacy of an oral investigational drug in patients with refractory metastatic colorectal cancer after receiving prior therapy with 5-fluorouracil in combination with irinotecan…
- Trial name
- NCT00044343
- Testing
- lapatinib
- Where
- 57 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome
Phase I Clinical Trial of DA-6886 in Healthy Male Subjects
DA-6886_IBS_I is a phase I, dose block-randomized, double-blind, placebo-controlled, single/multiple dosing, dose escalation clinical trial with open-labelled food effect study of single dose to investigate the safety…
- Trial name
- NCT01633723
- Testing
- DA-6886
- Where
- South Korea
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Ulcerative Colitis
A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis
To determine the dose or doses of PF-00547659 that will be the most effective to improve or halt the disease symptoms in patients with moderate to severe ulcerative colitis.
- Trial name
- TURANDOT (NCT01620255)
- Testing
- PF-00547659 SC Injection
- Where
- 190 sites in United States, Australia and 19 more
- Volunteers
- 357 people
- Sponsor
- Shire
Irritable Bowel Syndrome, Wheat Sensitivity
Effects of Wheat Breads on Symptoms of IBS, a Pilot Study
This is randomized pilot study comparing tolerability of yeast-baked wheat bread and sourdough wheat bread in irritable bowel syndrome.
- Trial name
- Wheat-IBS (NCT02572908)
- Testing
- Sourdough wheat bread, Regular yeast baked toast bread, Gluten-free diet
- Where
- Finland
- Volunteers
- 26 people
- Sponsor
- Oy Karl Fazer Ab
Metastatic Colorectal Cancer
SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer
This is an open label, single-arm, multi-center, phase II study of SHR-1210 in metastatic colorectal cancer patients with the recurrent lesion(s) post-surgery or the untreated mCRC.
- Trial name
- NCT03645876
- Testing
- SHR-1210, BP102, oxaliplatin
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Metastatic Colorectal Cancer
A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) of rivoceranib when used in combination with trifluridine/tipiracil in participants with mCRC and to assess progression-free survival (PFS) in…
- Trial name
- NCT04073615
- Testing
- Rivoceranib, Trifluridine/Tipiracil
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- Elevar Therapeutics
Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic
MGD019 DART® Protein in Unresectable/Metastatic Cancer
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of lorigerlimab.
- Conditions
- Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic, Cutaneous Melanoma, Colorectal Cancer
- Trial name
- NCT03761017
- Testing
- Lorigerlimab
- Where
- 39 sites in United States, Bulgaria and 3 more
- Volunteers
- 162 people
- Sponsor
- MacroGenics
Colitis, Ulcerative
Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC)
The purpose of this study is to prove the therapeutic equivalence and safety of once-daily 9 mg budesonide versus 3 g mesalazine in a 8-week treatment in patients with active ulcerative colitis.
- Trial name
- NCT00747110
- Testing
- budesonide, mesalazine
- Where
- Germany
- Volunteers
- 343 people
- Sponsor
- Dr. Falk Pharma GmbH
Colorectal Cancer
Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer
Randomized Single-blind Placebo-controlled Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer, With Different Doses and Regimens
- Trial name
- NCT02715882
- Testing
- CBLB502
- Where
- Russia
- Volunteers
- 40 people
- Sponsor
- BioLab 612 LLC
Inflammatory Bowel Disease, Colorectal Neoplasms
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
The primary objective of this study is to gather stool samples from subjects with inflammatory bowel disease (IBD) to be added to a test set of stool samples that will be utilized to help select molecular markers and determine…
- Conditions
- Inflammatory Bowel Disease, Colorectal Neoplasms, Digestive System Diseases, Colonic Diseases
- Trial name
- NCT02503696
- Testing
- Stool Collection Kit
- Where
- 29 sites in United States, Canada
- Volunteers
- 697 people
- Sponsor
- Exact Sciences Corporation
Metastatic Colorectal Cancer, Metastatic Cervical Cancer
Safety of Effivia®, a Bevacizumab Biosimilar
This is a post-marketing observational study aimed to evaluated the safety profile of Effivia®, a biosimilar of bevacizumab, in mexican patients with different types of cancer.
- Conditions
- Metastatic Colorectal Cancer, Metastatic Cervical Cancer, Non Squamous Non Small Cell Lung Cancer
- Trial name
- NCT06313268
- Testing
- Bevacizumab Biosimilar MB02
- Where
- 5 sites in Mexico
- Volunteers
- 83 people
- Sponsor
- Laboratorios Liomont
Progressive Metastatic Malignancies
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
This is a Phase 1, open-labeled, non-randomized, multi-center, competitive enrollment and dose-escalation study of ALT-801, the study drug.
- Trial name
- NCT00496860
- Testing
- ALT-801
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
Colon Cancer Metastatic, Head and Neck Cancer Metastatic
A Study of ADXS-NEO Expressing Personalized Tumor Antigens
This is a Phase 1, open-label, multicenter study of ADXS-NEO administered alone and in combination with pembrolizumab in participants with select advanced or metastatic solid tumors.
- Conditions
- Colon Cancer Metastatic, Head and Neck Cancer Metastatic, Metastatic Non-Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NEO (NCT03265080)
- Testing
- ADXS-NEO, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 13 people
- Sponsor
- Advaxis, Inc.